Daiichinkyo Co (TSE:4568) FFO


TSE:4568 Daiichi Sankyo Co Ltd TSE:4568
81 GF Score
Price 円2,535.50
GF Value 円6,074.95
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Daiichinkyo Co FFO?

FFO (Funds from operations) only applies to REITs.

TSE:4568
81GF Score
Daiichi Sankyo Co Ltd TSE:4568
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Daiichinkyo Co (TSE:4568) Overvalued in 2026?

Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued. The current stock price of 円2,535.50 is trading 58.3% below its estimated GF Value™ of 円6,074.95. GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.

Key valuation signals for TSE:4568:

  • FFO:
  • GF Value™: 円6,074.95 vs. price of 円2,535.50 (58.3% below fair value)
  • GF Score™: 81/100 with 3 warning signs

No single metric tells the full story. See the TSE:4568 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Daiichinkyo Co Business Description

Address 3-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
81GF Score

Get the complete analysis for TSE:4568

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,535.50
Price
円6,074.95
GF Value